**Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets**

Zhiyi Zhang and Chenqi Zhao

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53308

## **1. Introduction**

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1% of the population worldwide. RA mainly targets the synovial tissues of the small joints of the hands and feet, although larger joints are also affected. The disease is characterized by 1) proliferation of synovial fibroblasts, leading to synovial hyperplasia; 2) recruitment of in‐ flammatory cells into joint tissue, resulting in tissue destruction; and 3) excessive secretion of pro-inflammatory cytokines/chemokines, contributing directly to synovium inflamma‐ tion. While the etiology of RA remains unknown, inflammatory mediators appear to drive the evolution of the disease. In particular, TNF-α together with proinflammatory cytokines, including IL-1β and IL-6, have been shown to be pivotal in promoting cytokine, chemokine and matrix metalloproteinase production within the RA synovium, along with cellular acti‐ vation and joint erosion [1,2]. Given the complexity of the inflammatory cascade in the RA synovium, it is of great importance to identify novel biochemical signalling moieties that have the potential to constitute intracellular molecular checkpoints within the cell.

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite which is formed from sphingosine by sphingosine kinases (SphKs) and degraded by S1P phosphatases (SPPs) and S1P lyase (SPL). S1P is critically involved in both physiological and pathological processes. The lipid is implicated in many cellular processes including proliferation, apoptosis and mi‐ gration via binding to and activation of its G protein-coupled cell surface receptors. Altera‐ tions in S1P signalling as well as in the enzymes involved in its synthesis and metabolism have been observed in many types of pathological situations such as angiogenesis, metasta‐ sis, and autoimmunity. Accumulating evidence now suggests a role for S1P in various as‐

© 2013 Zhang and Zhao; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

pects of RA biology. This can involve, for example, activation of SphKs [3] and an elevated level of S1P [4] in the synovium and synovial fluids of patients with RA, as well as altera‐ tions in S1P signalling that lead to synovial fibroblast migration, proliferation, survival and production of proinflammatory cytokines/chemokines [4,5]. This review will highlight how S1P is involved in RA pathology and the mechanisms of its action. In addition, the therapeu‐ tic potential of drugs that alter S1P actions will be examined with reference to RA.

in sphingolipid metabolism and can be also synthesized de novo from serine and palmi‐ tate by the action of ceramide synthase [18]. Ceramide is, in turn, deacylated by cerami‐ dase to release sphingosine, which is then phosphorylated either by SphK1 or SphK2, to yield S1P. While both SphK1 and SphK2 can phosphorylate sphingosine, SphK1 produces most of the S1P [19]. SphKs can be activated by a large variety of agonists, such as TNF-α (reviewed in [20-22]). Activation of SphK1 leads to its translocation to the plasma mem‐ brane where its substrate sphingosine is located, resulting in the production of S1P [23,24]. S1P, in turn, activates specific S1P receptors present on the surface of the same cell or on nearby cells in autocrine and/or paracrine manners [20]. This "inside-out" signalling of intracellularly generated S1P is crucial for many of its functions [25]. S1P is degraded through two distinct mechanisms, the reversible dephosphorylation into sphingosine by SPPs, and the irreversible degradation by SPL to hexadecenal and ethanolamine phos‐ phate [26,27]. Consequently, the cellular levels of S1P are tightly regulated by its forma‐ tion from sphingosine through the activity of SphKs and its degradation through the activity of SPPs and SPL. In the basal state, the balance between S1P generation and deg‐

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

5

The mechanism by which S1P is exported to the outside of cells after synthesis is not fully understood. Several studies suggested the involvement of the ATP-binding cassette (ABC) family of transporters in S1P secretion [30-32]. It has been shown that its release from mast cells is regulated by ABCC1 [31] while the ABCA1 transporter is critical for release of S1P from astrocytes [32]. Altogether, these studies suggested that members of the family of ABC

S1P exerts diverse biological activities under physiological and pathological conditions via both intracellular and extracellular signalling pathways, but mostly the latter. To date, five cell surface G protein-coupled S1P receptors (S1P1-5), belonging to the endothelial differen‐ tiating gene (EDG) family, have been identified [13]. S1P receptors exhibit variable tissue distribution: S1P1, S1P2, and S1P3 are widely expressed in various tissues, whereas the ex‐ pression of S1P4 and S1P5 is more restricted to cells of the immune system and nervous sys‐ tem, respectively (reviewed in [33]). Each S1P receptor couples to a specific heterotrimeric G protein: Gi/o, Gq and G12/13. When activated, the G protein dissociates into its α and βγ subu‐ nits and transduces signals toward the downstream pathways. In particular, S1P1 is coupled predominantly to Gi/o, through which it activates signalling known to be essential for embry‐ onic blood vessel development as the murine S1P1 knockout is lethal at the embryonic stage, as a result of hemorrhage [34]. In addition, plasma S1P has been shown to elicit egress of lymphocytes into the blood in an S1P1-dependent manner [35] and to regulate basal and in‐ flammation-induced vascular leak *in vivo* [36]. S1P2 and S1P3 are linked predominantly to Gq and G12/13; knockout of both receptors in mice decreases litter size and survival rates [37]. S1P4 and S1P5 are the least studied receptors, although it is known that S1P4 is involved in T-cell proliferation [38] and S1P5 is required in natural killer cell trafficking [39]. More de‐ tailed information on the various signalling pathways triggered by S1P receptor activation

radation results in low cellular levels of S1P [28,29].

transporters may be important for the transport of S1P out of cells.

**2.2. S1P receptors and S1P receptor-mediated signalling**

## **2. S1P biology**

Sphingolipids are a class of complex, structurally-related compounds derived from sphin‐ goid bases, with hundreds of known class members; they represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Apart from their structural functions, sphingolipids have emerged as the source of important signalling molecules; these sphingolipid metabolites have important roles in stimulus/agonist-mediated signalling which regulate many cellular processes including inflammation, cell proliferation, apopto‐ sis, angiogenesis, and transformation [6]. Sphingolipid-mediated signalling also influences the pathophysiology of many diseases including cancer, and autoimmune and inflammatory diseases.

S1P is one of the most important sphingolipid metabolites. It was first identified as a potent second messenger in the early 1990s [7,8]. Since then, S1P has been shown to be involved in many important cell signalling pathways and physiological processes such as angiogenesis, cell migration and movement, cell survival and proliferation, cellular architecture, cellular contacts and adhesions, heart development, vascular development, atherogenesis, acute lung injury and acute respiratory distress, tumorogenicity and metastasis, and inflammation and immunity (reviewed in [9,10]). New tools, such as specific agonists and antagonists and the generation of targeted knockouts, have led to a surge of interest in the role of S1P in nu‐ merous diseases. Recent studies have shown, for example, that it modulates the pathophy‐ siological consequences of various autoimmune diseases, such as Sjogren's syndrome [11] and systemic sclerosis [12].

#### **2.1. S1P metabolism**

S1P is present at submicromolar concentrations in various biological fluids and tissues [13]. It is predominantly present in the platelets and erythrocytes in the blood, at concentrations of 100 nM to 4 μM [14], because the platelets lack the S1P degradation enzyme SPL [15]. Hu‐ man serum is also a rich source of S1P with concentrations ranging from 340 nM to 1 μM [16,17]. Moreover, the erythrocytes appear to be the cells mostly responsible for the storage and constant supply of plasma S1P [14].

S1P is produced intracellularly by a series of enzymatic reactions (Figure 1); all cells are able to generate it during the normal physiologic metabolism of sphingolipids. Sphingo‐ myelin hydrolysis is considered to be the first step in the pathway generating S1P. The re‐ action is catalyzed by sphingomyelinases yielding ceramide. Ceramide is the central step in sphingolipid metabolism and can be also synthesized de novo from serine and palmi‐ tate by the action of ceramide synthase [18]. Ceramide is, in turn, deacylated by cerami‐ dase to release sphingosine, which is then phosphorylated either by SphK1 or SphK2, to yield S1P. While both SphK1 and SphK2 can phosphorylate sphingosine, SphK1 produces most of the S1P [19]. SphKs can be activated by a large variety of agonists, such as TNF-α (reviewed in [20-22]). Activation of SphK1 leads to its translocation to the plasma mem‐ brane where its substrate sphingosine is located, resulting in the production of S1P [23,24]. S1P, in turn, activates specific S1P receptors present on the surface of the same cell or on nearby cells in autocrine and/or paracrine manners [20]. This "inside-out" signalling of intracellularly generated S1P is crucial for many of its functions [25]. S1P is degraded through two distinct mechanisms, the reversible dephosphorylation into sphingosine by SPPs, and the irreversible degradation by SPL to hexadecenal and ethanolamine phos‐ phate [26,27]. Consequently, the cellular levels of S1P are tightly regulated by its forma‐ tion from sphingosine through the activity of SphKs and its degradation through the activity of SPPs and SPL. In the basal state, the balance between S1P generation and deg‐ radation results in low cellular levels of S1P [28,29].

The mechanism by which S1P is exported to the outside of cells after synthesis is not fully understood. Several studies suggested the involvement of the ATP-binding cassette (ABC) family of transporters in S1P secretion [30-32]. It has been shown that its release from mast cells is regulated by ABCC1 [31] while the ABCA1 transporter is critical for release of S1P from astrocytes [32]. Altogether, these studies suggested that members of the family of ABC transporters may be important for the transport of S1P out of cells.

#### **2.2. S1P receptors and S1P receptor-mediated signalling**

pects of RA biology. This can involve, for example, activation of SphKs [3] and an elevated level of S1P [4] in the synovium and synovial fluids of patients with RA, as well as altera‐ tions in S1P signalling that lead to synovial fibroblast migration, proliferation, survival and production of proinflammatory cytokines/chemokines [4,5]. This review will highlight how S1P is involved in RA pathology and the mechanisms of its action. In addition, the therapeu‐

Sphingolipids are a class of complex, structurally-related compounds derived from sphin‐ goid bases, with hundreds of known class members; they represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Apart from their structural functions, sphingolipids have emerged as the source of important signalling molecules; these sphingolipid metabolites have important roles in stimulus/agonist-mediated signalling which regulate many cellular processes including inflammation, cell proliferation, apopto‐ sis, angiogenesis, and transformation [6]. Sphingolipid-mediated signalling also influences the pathophysiology of many diseases including cancer, and autoimmune and inflammatory

S1P is one of the most important sphingolipid metabolites. It was first identified as a potent second messenger in the early 1990s [7,8]. Since then, S1P has been shown to be involved in many important cell signalling pathways and physiological processes such as angiogenesis, cell migration and movement, cell survival and proliferation, cellular architecture, cellular contacts and adhesions, heart development, vascular development, atherogenesis, acute lung injury and acute respiratory distress, tumorogenicity and metastasis, and inflammation and immunity (reviewed in [9,10]). New tools, such as specific agonists and antagonists and the generation of targeted knockouts, have led to a surge of interest in the role of S1P in nu‐ merous diseases. Recent studies have shown, for example, that it modulates the pathophy‐ siological consequences of various autoimmune diseases, such as Sjogren's syndrome [11]

S1P is present at submicromolar concentrations in various biological fluids and tissues [13]. It is predominantly present in the platelets and erythrocytes in the blood, at concentrations of 100 nM to 4 μM [14], because the platelets lack the S1P degradation enzyme SPL [15]. Hu‐ man serum is also a rich source of S1P with concentrations ranging from 340 nM to 1 μM [16,17]. Moreover, the erythrocytes appear to be the cells mostly responsible for the storage

S1P is produced intracellularly by a series of enzymatic reactions (Figure 1); all cells are able to generate it during the normal physiologic metabolism of sphingolipids. Sphingo‐ myelin hydrolysis is considered to be the first step in the pathway generating S1P. The re‐ action is catalyzed by sphingomyelinases yielding ceramide. Ceramide is the central step

tic potential of drugs that alter S1P actions will be examined with reference to RA.

**2. S1P biology**

4 Innovative Rheumatology

diseases.

and systemic sclerosis [12].

and constant supply of plasma S1P [14].

**2.1. S1P metabolism**

S1P exerts diverse biological activities under physiological and pathological conditions via both intracellular and extracellular signalling pathways, but mostly the latter. To date, five cell surface G protein-coupled S1P receptors (S1P1-5), belonging to the endothelial differen‐ tiating gene (EDG) family, have been identified [13]. S1P receptors exhibit variable tissue distribution: S1P1, S1P2, and S1P3 are widely expressed in various tissues, whereas the ex‐ pression of S1P4 and S1P5 is more restricted to cells of the immune system and nervous sys‐ tem, respectively (reviewed in [33]). Each S1P receptor couples to a specific heterotrimeric G protein: Gi/o, Gq and G12/13. When activated, the G protein dissociates into its α and βγ subu‐ nits and transduces signals toward the downstream pathways. In particular, S1P1 is coupled predominantly to Gi/o, through which it activates signalling known to be essential for embry‐ onic blood vessel development as the murine S1P1 knockout is lethal at the embryonic stage, as a result of hemorrhage [34]. In addition, plasma S1P has been shown to elicit egress of lymphocytes into the blood in an S1P1-dependent manner [35] and to regulate basal and in‐ flammation-induced vascular leak *in vivo* [36]. S1P2 and S1P3 are linked predominantly to Gq and G12/13; knockout of both receptors in mice decreases litter size and survival rates [37]. S1P4 and S1P5 are the least studied receptors, although it is known that S1P4 is involved in T-cell proliferation [38] and S1P5 is required in natural killer cell trafficking [39]. More de‐ tailed information on the various signalling pathways triggered by S1P receptor activation can be found in previous reviews [40,41]. The five known S1P receptors can lead to activa‐ tion of different downstream targets, such as Rac, ERK, PI3K, adenylyl cyclase, phospholi‐ pase-C, Rho or JNK, resulting in the abovementioned cellular responses [42]. The extracellular pathways mediated by each S1P-specific receptor are common; however, given the existence of agonists and antagonists that exhibit receptor specificity, it is probable that the S1P receptors are not totally redundant [43]. Upon binding to one of the five known cell surface receptors, S1P initiates signal transduction leading to various cellular responses.

S1P is widely expressed in RA synovium. Elevated levels were detected in both synovial tis‐ sue and synovial fluids from patients with RA [4,48]. Moreover, the S1P content in synovial fluids from patients with RA was compared to that from patients with osteoarthritis (OA), a degenerative joint disease [4]. S1P levels were shown to be much higher in synovial fluids of RA patients than in those of OA patients. In that study, the S1P level in RA synovial fluids was even higher than those in serum or plasma from normal donors. A similar experiment was performed with a different experimental strategy, in which the S1P level in RA synovial fluids was five fold higher than that in OA synovial fluids [48]. Peripheral blood B lympho‐ blastoid cell lines from patients with RA exhibited a high level of S1P level as well [47]. This increase in S1P level could be responsible for the recruitment and retention of the immune

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

**RA OA Normal Experimental StrategyReference**

N/A Chromatography [47]

N/A Sphk enzymatic activity

Weakly positive N/A Immunofluorescence [3]

Weak expression Weak expression immunostaining [4]

**Table 1.** SphK expression/activity, S1P levels, and S1P receptor expression in synovium of RA, OA, and normal donors.

assay

[47]

http://dx.doi.org/10.5772/53308

7

17.51±4.23 μM 3.45±0.85 μM N/A Competitive ELISA [48]

1,078.92 p*M*/ml 765.01 p*M*/ml N/A HPLC [4]

infiltrates in the synovium.

Increased level in LDLs compared to normal control

cells

cells

More SphK2 positive cells than those in OA

Markedly enhanced expression than that in OA

N/A: not applicable or not available

Markedly increased enzymatic activity in LDLs compared to normal control

**S1P content in synovial fluids**

**S1P intracellular level in synovial**

**SphK activity in synovial cells**

**SphK expression in synovial fibroblasts**

**S1P1 receptor expression in synovial tissue**

**cells**

S1P also exerts its action as a second messenger via intracellular pathways. For example, it intracellularly targets the histone deacetylases HDACs, regulating specific and contextual chromatin states that impact gene transcription [44]. S1P has been shown to promote growth and survival, independently from its G protein-coupled receptors, in mouse embryonic fi‐ broblasts devoid of S1P receptors [35]. There is also evidence supporting a role for intracel‐ lular S1P in calcium mobilization [45].

## **3. Alteration of S1P in rheumatoid arthritis**

TNF-α is the predominant proinflammatory cytokine in RA. TNF-α can activate SphK, which leads to the production of S1P [46]. Indeed, SphK1, SphK2 [3,47] and S1P levels [48] are elevated in the synovium of patients with RA. Moreover, administration of S1P to RA synovial fibroblasts causes their proliferation, survival, and migration, as well as cytokine/ chemokine and other proinflammatory mediator production [4,5]. The findings suggest that S1P may play a role in RA pathology (Figure 2).

#### **3.1. SphK activity and S1P levels in RA synovium**

Activated SphKs and elevated S1P levels are associated to RA (Table 1). For instance, in‐ creased SphK1 expression and activity was found in RA B lymphoblastoid cell lines, and identified as the underlying mechanism of impaired Fas-mediated death signalling in RA [47]. More recently, SphK2 has been shown to be strongly expressed in RA synovial fibro‐ blasts *in vivo* and *in vitro*, which is associated with upregulation of S1P [3]. Suppression of SphK2 by siRNA results in a more aggressive disease and greater secretion of proinflamma‐ tory cytokines, such as IL-6, TNF-α and IFN-γ in a murine collagen-induced arthritis (CIA) model [49]. Of more interest, in a murine CIA model, administration of a pharmacological SphK inhibitor, *N*,*N*-dimethylsphingosine (DMS), and an siRNA approach to knockdown SphK1 isoform markedly suppressed joint pathologies such as adjacent cartilage and bone erosion, synovial hyperplasia, and inflammatory infiltration into the joint compartment [49].

At present, evidence for roles in RA of other S1P metabolic enzymes, such as SPPs and SPL, is limited. However, up-regulation of SPP2 was detected in samples of skin lesions from pa‐ tients with psoriasis, a chronic inflammatory skin disease [50]. Interestingly, an elevated mRNA expression of SPP1 and SPL was observed in RA synovial fibroblasts, as compared to non-arthritic synovial fibroblasts (Zhao et al., unpublished data).

S1P is widely expressed in RA synovium. Elevated levels were detected in both synovial tis‐ sue and synovial fluids from patients with RA [4,48]. Moreover, the S1P content in synovial fluids from patients with RA was compared to that from patients with osteoarthritis (OA), a degenerative joint disease [4]. S1P levels were shown to be much higher in synovial fluids of RA patients than in those of OA patients. In that study, the S1P level in RA synovial fluids was even higher than those in serum or plasma from normal donors. A similar experiment was performed with a different experimental strategy, in which the S1P level in RA synovial fluids was five fold higher than that in OA synovial fluids [48]. Peripheral blood B lympho‐ blastoid cell lines from patients with RA exhibited a high level of S1P level as well [47]. This increase in S1P level could be responsible for the recruitment and retention of the immune infiltrates in the synovium.

can be found in previous reviews [40,41]. The five known S1P receptors can lead to activa‐ tion of different downstream targets, such as Rac, ERK, PI3K, adenylyl cyclase, phospholi‐ pase-C, Rho or JNK, resulting in the abovementioned cellular responses [42]. The extracellular pathways mediated by each S1P-specific receptor are common; however, given the existence of agonists and antagonists that exhibit receptor specificity, it is probable that the S1P receptors are not totally redundant [43]. Upon binding to one of the five known cell surface receptors, S1P initiates signal transduction leading to various cellular responses.

S1P also exerts its action as a second messenger via intracellular pathways. For example, it intracellularly targets the histone deacetylases HDACs, regulating specific and contextual chromatin states that impact gene transcription [44]. S1P has been shown to promote growth and survival, independently from its G protein-coupled receptors, in mouse embryonic fi‐ broblasts devoid of S1P receptors [35]. There is also evidence supporting a role for intracel‐

TNF-α is the predominant proinflammatory cytokine in RA. TNF-α can activate SphK, which leads to the production of S1P [46]. Indeed, SphK1, SphK2 [3,47] and S1P levels [48] are elevated in the synovium of patients with RA. Moreover, administration of S1P to RA synovial fibroblasts causes their proliferation, survival, and migration, as well as cytokine/ chemokine and other proinflammatory mediator production [4,5]. The findings suggest that

Activated SphKs and elevated S1P levels are associated to RA (Table 1). For instance, in‐ creased SphK1 expression and activity was found in RA B lymphoblastoid cell lines, and identified as the underlying mechanism of impaired Fas-mediated death signalling in RA [47]. More recently, SphK2 has been shown to be strongly expressed in RA synovial fibro‐ blasts *in vivo* and *in vitro*, which is associated with upregulation of S1P [3]. Suppression of SphK2 by siRNA results in a more aggressive disease and greater secretion of proinflamma‐ tory cytokines, such as IL-6, TNF-α and IFN-γ in a murine collagen-induced arthritis (CIA) model [49]. Of more interest, in a murine CIA model, administration of a pharmacological SphK inhibitor, *N*,*N*-dimethylsphingosine (DMS), and an siRNA approach to knockdown SphK1 isoform markedly suppressed joint pathologies such as adjacent cartilage and bone erosion, synovial hyperplasia, and inflammatory infiltration into the joint compartment [49].

At present, evidence for roles in RA of other S1P metabolic enzymes, such as SPPs and SPL, is limited. However, up-regulation of SPP2 was detected in samples of skin lesions from pa‐ tients with psoriasis, a chronic inflammatory skin disease [50]. Interestingly, an elevated mRNA expression of SPP1 and SPL was observed in RA synovial fibroblasts, as compared

to non-arthritic synovial fibroblasts (Zhao et al., unpublished data).

lular S1P in calcium mobilization [45].

6 Innovative Rheumatology

**3. Alteration of S1P in rheumatoid arthritis**

S1P may play a role in RA pathology (Figure 2).

**3.1. SphK activity and S1P levels in RA synovium**


**Table 1.** SphK expression/activity, S1P levels, and S1P receptor expression in synovium of RA, OA, and normal donors.

#### **3.2. S1P receptor expression in synovial fibroblasts**

Synovial fibroblasts or fibroblast-like synovial synoviocytes (FLS) are key contributors to RA chronic inflammation due to their abnormal growth and erosive activity. During RA disease progression, these cells become hyperplastic, closely interact with infiltrated immune cells to form the aggressive pannus tissue that invades and degrades the cartilage and bone and eventually promotes joint destruction (reviewed in [51]). Synovial fibroblasts also contribute to the local production of cytokines/chemokines, small molecule mediators of inflammation, and proteolytic enzymes that degrade the extracellular matrix [52].

flammatory cytokines and chemokines such as TNF-α, IL-1β, IL-6, MMPs, and receptor acti‐

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

9

S1P is able to stimulate the production of other inflammatory mediators, such as PGE2, and of its metabolic enzymes cyclooxygenases (COXs) in RA synovial fibroblasts [4,53]. PGE2 is an autocrine lipid mediator derived from arachidonic acid metabolism by COX-1 or COX-2 [59]. The inflammation characteristic of RA is actually closely associated to the production of PGE2 by synovial fibroblasts, as PGE2 stimulates angiogenesis in rheumatoid synovium [60] and triggers bone resorption by osteoclasts [61]. Thus, S1P may aggravate synovial hyper‐ plasia, inflammation and angiogenesis through the induction of COX-2 and PGE2 in RA

**3.4. Upregulation of immune cell recruitment and retention by S1P in the RA synovium**

Recruitment and retention of inflammatory cells, such as neutrophils, monocytes and T lymphocytes, are other fundamental features of RA synovitis. This process is coordinated by the presence of chemo-attractant proteins at the site of inflammation, assisted by the expression of adhesion molecules. Chemokines and other small chemo-attractant mole‐ cules are abundant in the RA synovium and can be produced by synovial fibroblasts in the intimal lining. S1P, as a chemo-attractant, plays a pivotal role in the immune cell egression. S1P1, for example, is essential for lymphocyte recirculation since it regulates lymphocyte egress from both thymus and peripheral lymphoid organs [62,63]. As S1P ex‐ ists at lower levels in tissues and higher levels in the blood and lymph, it is suggested that the S1P gradient between tissues and the blood/lymph drives such a migration. Like‐ wise, the elevated S1P levels in the synovial fluid of RA patients [48] could be responsible for the recruitment and retention of the immune infiltrates in the RA synovium. Indeed, inhibition of S1P1 down-regulated inflammatory cell accumulation in an adjuvant-induced

S1P may also contribute indirectly to the recruitment and retention of inflammatory cells in‐ to RA synovium by stimulating the secretion of other chemo-attractants. In RA, the recruit‐ ment of immune cells into the synovium may be due to the large amount of CC and CXC chemokines produced by activated cells of the synovial lining. In particular, IL-8 exhibits se‐ lective chemotactic activity for neutrophils, whereas MCP-1, MIP-1α, -1β and RANTES pri‐ marily attract monocytes. RA synovial fibroblasts do not secrete detectable levels of cytokines or chemokines, except for low amounts of MCP-1 in the resting state; upon treat‐ ment with S1P, however, the secretion of IL-8, IL-6, MCP-1 and RANTES is strongly in‐ duced, indicating S1P contribution to and/or amplification of the secretion of chemokines by cells of the inflamed synovium [5]. Since immune cells express a wide repertoire of chemo‐ kine receptors, including those of IL-8, MCP-1, SDF-1α, IP-10 and RANTES [65], S1P may indirectly drive the recruitment and retention of inflammatory cells in RA by this chemokine secretion. Indeed, a bioactive lipid structurally-related to S1P, lysophosphatidic acid (LPA), is able to recruit leukocytes into an *in vivo* inflammatory site by stimulating inflammatory

vator of NF-κB ligand (RANKL) [57,58].

arthritis (AIA) animal model [64].

cytokine/chemokine secretion [66].

synovial tissues.

RA synovial fibroblasts have been reported to express three of five known S1P receptors, S1P1-3 [4,5,53]. Expression of S1P1 in RA inflamed synovial tissue is significantly higher than that in OA synovial tissue [4]. Of more interest, pretreatment of RA synovial fibroblasts with TNF-α, the cytokine well-recognized to be critical in RA, results in up-regulation of S1P3 receptor expression in synovial fibroblasts, which likely contributes to the synergistic production of inflammatory cytokines/chemokines, migration (or invasion) and survival of these cells upon subsequent exposure to S1P [5]. Thus, it seems that the elevated TNF-α lev‐ els observed in the synovial fluid of RA patients could make synovial fibroblasts more re‐ sponsive to increases of S1P in RA synovium; in turn, the enhanced responsiveness to S1P through the S1P3 receptor could increase synovial fibroblast survival, migration and pro‐ duction of cytokines/chemokines, processes that all likely contribute to the pathology of RA.

#### **3.3. Influence of S1P on the secretion of proinflammatory cytokines/chemokines and other proinflammatory mediators by synovial fibroblasts**

One key feature of RA is the large amounts of pro-inflammatory cytokines and chemokines produced by activated synovial cells. These cytokines/chemokines may directly contribute to cartilage and bone erosion by promoting matrix metalloproteinase (MMP) production and chondrocyte/osteoclast destruction function [51]. S1P can stimulate synovial fibroblasts to release various inflammatory mediators, including cytokines, chemokines, and prosta‐ glandin E2 (PGE2) [4,5]. S1P administration notably stimulates the synovial fibroblast secre‐ tion of IL-8, IL-6, MCP-1 and RANTES via S1P2 and S1P3 receptors and through modulation of p38, ERK, and Rho kinase activities [5]. The S1P-induced cytokine/chemokine secretion and S1P receptor-mediated signalling pathways were further suggested as the driving force for synovial fibroblast invasion into the surrounding tissue [5]. Moreover, inhibition of S1P production by a potent SphK1 inhibitor, DMS, significantly suppresses production of these cytokines [48]. The effect of S1P on cytokine secretion is further amplified by TNF-α [5], sug‐ gesting that the cytokine-rich environment of the inflamed synovium may synergize with S1P signalling to exacerbate the disease process [5].

In addition, S1P has been found to indirectly stimulate IL-17 secretion by activating T-cell receptor-activated CD4 T cells [54]. IL-17 is produced by cultured peripheral blood mononu‐ clear cells (PBMC) and synovial membrane cells, and elevated levels of IL-17 are detected in the synovial fluid of RA patients [54,55]. It was reported that IL-17-deficient mice showed resistance to CIA [56]. Furthermore, IL-17 was demonstrated to contribute to the severity of synovial inflammation and bone destruction in RA by stimulating the production of proin‐ flammatory cytokines and chemokines such as TNF-α, IL-1β, IL-6, MMPs, and receptor acti‐ vator of NF-κB ligand (RANKL) [57,58].

**3.2. S1P receptor expression in synovial fibroblasts**

8 Innovative Rheumatology

and proteolytic enzymes that degrade the extracellular matrix [52].

**other proinflammatory mediators by synovial fibroblasts**

S1P signalling to exacerbate the disease process [5].

Synovial fibroblasts or fibroblast-like synovial synoviocytes (FLS) are key contributors to RA chronic inflammation due to their abnormal growth and erosive activity. During RA disease progression, these cells become hyperplastic, closely interact with infiltrated immune cells to form the aggressive pannus tissue that invades and degrades the cartilage and bone and eventually promotes joint destruction (reviewed in [51]). Synovial fibroblasts also contribute to the local production of cytokines/chemokines, small molecule mediators of inflammation,

RA synovial fibroblasts have been reported to express three of five known S1P receptors, S1P1-3 [4,5,53]. Expression of S1P1 in RA inflamed synovial tissue is significantly higher than that in OA synovial tissue [4]. Of more interest, pretreatment of RA synovial fibroblasts with TNF-α, the cytokine well-recognized to be critical in RA, results in up-regulation of S1P3 receptor expression in synovial fibroblasts, which likely contributes to the synergistic production of inflammatory cytokines/chemokines, migration (or invasion) and survival of these cells upon subsequent exposure to S1P [5]. Thus, it seems that the elevated TNF-α lev‐ els observed in the synovial fluid of RA patients could make synovial fibroblasts more re‐ sponsive to increases of S1P in RA synovium; in turn, the enhanced responsiveness to S1P through the S1P3 receptor could increase synovial fibroblast survival, migration and pro‐ duction of cytokines/chemokines, processes that all likely contribute to the pathology of RA.

**3.3. Influence of S1P on the secretion of proinflammatory cytokines/chemokines and**

One key feature of RA is the large amounts of pro-inflammatory cytokines and chemokines produced by activated synovial cells. These cytokines/chemokines may directly contribute to cartilage and bone erosion by promoting matrix metalloproteinase (MMP) production and chondrocyte/osteoclast destruction function [51]. S1P can stimulate synovial fibroblasts to release various inflammatory mediators, including cytokines, chemokines, and prosta‐ glandin E2 (PGE2) [4,5]. S1P administration notably stimulates the synovial fibroblast secre‐ tion of IL-8, IL-6, MCP-1 and RANTES via S1P2 and S1P3 receptors and through modulation of p38, ERK, and Rho kinase activities [5]. The S1P-induced cytokine/chemokine secretion and S1P receptor-mediated signalling pathways were further suggested as the driving force for synovial fibroblast invasion into the surrounding tissue [5]. Moreover, inhibition of S1P production by a potent SphK1 inhibitor, DMS, significantly suppresses production of these cytokines [48]. The effect of S1P on cytokine secretion is further amplified by TNF-α [5], sug‐ gesting that the cytokine-rich environment of the inflamed synovium may synergize with

In addition, S1P has been found to indirectly stimulate IL-17 secretion by activating T-cell receptor-activated CD4 T cells [54]. IL-17 is produced by cultured peripheral blood mononu‐ clear cells (PBMC) and synovial membrane cells, and elevated levels of IL-17 are detected in the synovial fluid of RA patients [54,55]. It was reported that IL-17-deficient mice showed resistance to CIA [56]. Furthermore, IL-17 was demonstrated to contribute to the severity of synovial inflammation and bone destruction in RA by stimulating the production of proin‐ S1P is able to stimulate the production of other inflammatory mediators, such as PGE2, and of its metabolic enzymes cyclooxygenases (COXs) in RA synovial fibroblasts [4,53]. PGE2 is an autocrine lipid mediator derived from arachidonic acid metabolism by COX-1 or COX-2 [59]. The inflammation characteristic of RA is actually closely associated to the production of PGE2 by synovial fibroblasts, as PGE2 stimulates angiogenesis in rheumatoid synovium [60] and triggers bone resorption by osteoclasts [61]. Thus, S1P may aggravate synovial hyper‐ plasia, inflammation and angiogenesis through the induction of COX-2 and PGE2 in RA synovial tissues.

#### **3.4. Upregulation of immune cell recruitment and retention by S1P in the RA synovium**

Recruitment and retention of inflammatory cells, such as neutrophils, monocytes and T lymphocytes, are other fundamental features of RA synovitis. This process is coordinated by the presence of chemo-attractant proteins at the site of inflammation, assisted by the expression of adhesion molecules. Chemokines and other small chemo-attractant mole‐ cules are abundant in the RA synovium and can be produced by synovial fibroblasts in the intimal lining. S1P, as a chemo-attractant, plays a pivotal role in the immune cell egression. S1P1, for example, is essential for lymphocyte recirculation since it regulates lymphocyte egress from both thymus and peripheral lymphoid organs [62,63]. As S1P ex‐ ists at lower levels in tissues and higher levels in the blood and lymph, it is suggested that the S1P gradient between tissues and the blood/lymph drives such a migration. Like‐ wise, the elevated S1P levels in the synovial fluid of RA patients [48] could be responsible for the recruitment and retention of the immune infiltrates in the RA synovium. Indeed, inhibition of S1P1 down-regulated inflammatory cell accumulation in an adjuvant-induced arthritis (AIA) animal model [64].

S1P may also contribute indirectly to the recruitment and retention of inflammatory cells in‐ to RA synovium by stimulating the secretion of other chemo-attractants. In RA, the recruit‐ ment of immune cells into the synovium may be due to the large amount of CC and CXC chemokines produced by activated cells of the synovial lining. In particular, IL-8 exhibits se‐ lective chemotactic activity for neutrophils, whereas MCP-1, MIP-1α, -1β and RANTES pri‐ marily attract monocytes. RA synovial fibroblasts do not secrete detectable levels of cytokines or chemokines, except for low amounts of MCP-1 in the resting state; upon treat‐ ment with S1P, however, the secretion of IL-8, IL-6, MCP-1 and RANTES is strongly in‐ duced, indicating S1P contribution to and/or amplification of the secretion of chemokines by cells of the inflamed synovium [5]. Since immune cells express a wide repertoire of chemo‐ kine receptors, including those of IL-8, MCP-1, SDF-1α, IP-10 and RANTES [65], S1P may indirectly drive the recruitment and retention of inflammatory cells in RA by this chemokine secretion. Indeed, a bioactive lipid structurally-related to S1P, lysophosphatidic acid (LPA), is able to recruit leukocytes into an *in vivo* inflammatory site by stimulating inflammatory cytokine/chemokine secretion [66].

#### **3.5. Promotion of proliferation and/or survival of synovial fibroblasts, B lymphocytes, and chondrocytes by S1P in the RA synovium**

erosion [87,88]. In addition to the RANK/RANKL pathway, many cytokines (such as TNF-α, IL-6, and IL-17) and growth factors elaborated by inflamed synovial tissues may contribute

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

11

S1P has been found to induce chemotaxis of osteoclast precursors and osteoclastogenesis *in vitro* [90] and *in vivo* [91]. In a bone marrow-derived macrophage and osteoblast coculture system, for instance, S1P addition greatly increased osteoclastogenesis by increasing RANKL in osteoblasts via cyclooxygenase-2 and PGE2 regulation [90]. S1P also chemoat‐ tracted osteoblasts and enhanced their survival [90]. Moreover, S1P controls the migratory behaviour of osteoclast precursors between bone tissues and the blood stream, dynamically regulating bone mineral homeostasis via S1P receptors. Cells with the properties of osteo‐ clast precursors indeed express functional S1P1 receptors and exhibit positive chemotaxis along an S1P gradient *in vitro* [92]. On the other hand, S1P2 requires a higher concentration of S1P for activation and induces negative chemotactic responses to S1P gradients [91]. S1P2

activation causes cells to move from the bloodstream into bone marrow cavities [91].

Both CIA and AIA are well-established models for studying RA. Administration of the S1P receptor agonist FYT720, which down-regulates S1P receptors, in rat CIA and AIA models inhibits rat hind paw oedema and joint destruction and decreases lymphocyte invasion into the joints [93,94]. In addition to receptor modulation, non-specific inhibition of SphK with DMS in a murine CIA model has been shown to significantly reduce adjacent cartilage and bone erosion, synovial hyperplasia, and inflammatory infiltration into the joint compart‐ ment [48,49]. Moreover, suppression of SphK1 via siRNA knockdown results in similar re‐ duction in joint pathology, serum levels of IL-6, TNF-α, IFN-γ and S1P, and the *in vitro* production of these proinflammatory mediators in response to collagen [48,49]. In another murine arthritis model, the transgenic human TNF-α model that develops spontaneous ero‐ sive arthritis, Sphk1-deficient mice exhibit significantly less synovial inflammation and joint

Interestingly, SphK isoforms may play different roles in RA. In a murine CIA model, downregulating SphK1 via specific small interfering RNA (siRNA) significantly reduced the inci‐ dence, disease severity, and articular inflammation. Treatment with SphK1 siRNA also down-regulated serum levels of S1P, IL-6, TNF-α, IFN-γ, and IgG2a anticollagen antibody [49]. On the other hand, mice receiving SphK2 siRNA developed a more aggressive disease, and higher serum levels of IL-6, TNF-α, and IFN-γ, when compared with control siRNA re‐ cipients. These results suggest distinct immunomodulatory roles for SphK1 and SphK2 in the development of inflammatory arthritis via the regulation of the release of proinflamma‐

S1P metabolism and SphK/S1P/S1P receptor axis-mediated signalling pathways in rheuma‐ toid arthritis synovium and the potential role of S1P in RA pathogenesis are illustrated in

to osteoclast differentiation and activation in RA [89].

**3.7. SphKs and S1P in experimental arthritis**

pathology than the wild-type mice [95].

tory cytokines and T cell responses.

Figure 1 and Figure 2, respectively.

Abnormal growth of synovial fibroblasts and chondrocytes has been suggested to contribute directly to hyperplasia of the rheumatoid synovium [67]. The growth in RA of the synovial fibroblast population is likely attributable to an imbalance between cell proliferation, surviv‐ al, and death. In fact, synovial fibroblast proliferation is difficult to demonstrate in RA. Nonetheless, limited numbers of mitotic figures or cells expressing cell cycle markers sug‐ gest that synovial fibroblast DNA synthesis is not a major influence [68,69]. Instead, the RA synovial environment promotes survival of these cells and discourages their depletion through apoptosis. S1P, through S1P1, protects synovial fibroblasts from apoptosis [5]. Thus, the ability of S1P to promote synovial fibroblasts survival, whether or not this agent can also increase cell proliferation, could contribute to RA pannus hyperplasia [70].

B lymphocytes play an important role in the pathogenesis of RA. B-cell accumulation and maturation in the inflamed synovium can form ectopic germinal centers [71-73] and activate T cells [74]. Moreover, mature plasma cells secrete autoantibodies, such as the rheumatoid factor, which are key features of RA [75]. The importance of B cells in RA is illustrated by the success obtained when targeting CD-20-positive B cells with the chimeric monoclonal anti-CD20 antibody, rituximab [76]. In that study, a single short course of rituximab, either alone or in combination with cyclophosphamide or continuing methotrexate, provided pa‐ tients with significant improvements in disease symptoms, a reduction in B-cell numbers, rheumatoid factors, and total immunoglobulin levels. S1P appears capable of increasing cell survival and inhibiting apoptosis of B lymphocytes derived from RA patients, as these cells are uniquely resistant to Fas-mediated apoptosis [47]. This effect is due to an increased ac‐ tivity of SphK1 and an overproduction of S1P. In a murine experimental arthritis model, ad‐ ministration of SphK inhibitor, DMS, and of SphK1 siRNA significantly decreased the production of anticollagen IgG2a in the mouse serum [48,49].

S1P was also reported to induce chondrocyte proliferation through stimulation of COX-2 and PGE2 production and via activation of ERK [77,78], and was thus suggested to be able to modulate cartilage homeostasis.

#### **3.6. Contribution of S1P to osteoclastogenesis**

Pathologic bone loss is a common feature of RA in which progressive destruction of bone is associated with joint inflammation. Focal bone erosion occurs at the pannus-bone interface and in the immediate subchondral bone early in RA, and is associated over time with signif‐ icant morbidity for patients [79]. Bone-resorbing osteoclasts have been identified as impor‐ tant effector cells in inflammation-induced bone loss in both experimental animal models and human RA. Osteoclasts are derived from hematopoietic precursor cells of the myeloid lineage [80,81]. In normal skeletal remodelling, the balance between bone resorption by os‐ teoclasts and bone formation by osteoblasts is critically regulated [82-84] and osteoclast dif‐ ferentiation is dependent on the presence of two key factors, RANKL and colonystimulating factor-1(CSF-1), provided by cells of the osteoblast lineage [81,85,86]. In experimental animal models of arthritis, osteoclasts have been observed at sites of focal bone erosion [87,88]. In addition to the RANK/RANKL pathway, many cytokines (such as TNF-α, IL-6, and IL-17) and growth factors elaborated by inflamed synovial tissues may contribute to osteoclast differentiation and activation in RA [89].

S1P has been found to induce chemotaxis of osteoclast precursors and osteoclastogenesis *in vitro* [90] and *in vivo* [91]. In a bone marrow-derived macrophage and osteoblast coculture system, for instance, S1P addition greatly increased osteoclastogenesis by increasing RANKL in osteoblasts via cyclooxygenase-2 and PGE2 regulation [90]. S1P also chemoat‐ tracted osteoblasts and enhanced their survival [90]. Moreover, S1P controls the migratory behaviour of osteoclast precursors between bone tissues and the blood stream, dynamically regulating bone mineral homeostasis via S1P receptors. Cells with the properties of osteo‐ clast precursors indeed express functional S1P1 receptors and exhibit positive chemotaxis along an S1P gradient *in vitro* [92]. On the other hand, S1P2 requires a higher concentration of S1P for activation and induces negative chemotactic responses to S1P gradients [91]. S1P2 activation causes cells to move from the bloodstream into bone marrow cavities [91].

#### **3.7. SphKs and S1P in experimental arthritis**

**3.5. Promotion of proliferation and/or survival of synovial fibroblasts, B lymphocytes,**

increase cell proliferation, could contribute to RA pannus hyperplasia [70].

production of anticollagen IgG2a in the mouse serum [48,49].

to modulate cartilage homeostasis.

**3.6. Contribution of S1P to osteoclastogenesis**

Abnormal growth of synovial fibroblasts and chondrocytes has been suggested to contribute directly to hyperplasia of the rheumatoid synovium [67]. The growth in RA of the synovial fibroblast population is likely attributable to an imbalance between cell proliferation, surviv‐ al, and death. In fact, synovial fibroblast proliferation is difficult to demonstrate in RA. Nonetheless, limited numbers of mitotic figures or cells expressing cell cycle markers sug‐ gest that synovial fibroblast DNA synthesis is not a major influence [68,69]. Instead, the RA synovial environment promotes survival of these cells and discourages their depletion through apoptosis. S1P, through S1P1, protects synovial fibroblasts from apoptosis [5]. Thus, the ability of S1P to promote synovial fibroblasts survival, whether or not this agent can also

B lymphocytes play an important role in the pathogenesis of RA. B-cell accumulation and maturation in the inflamed synovium can form ectopic germinal centers [71-73] and activate T cells [74]. Moreover, mature plasma cells secrete autoantibodies, such as the rheumatoid factor, which are key features of RA [75]. The importance of B cells in RA is illustrated by the success obtained when targeting CD-20-positive B cells with the chimeric monoclonal anti-CD20 antibody, rituximab [76]. In that study, a single short course of rituximab, either alone or in combination with cyclophosphamide or continuing methotrexate, provided pa‐ tients with significant improvements in disease symptoms, a reduction in B-cell numbers, rheumatoid factors, and total immunoglobulin levels. S1P appears capable of increasing cell survival and inhibiting apoptosis of B lymphocytes derived from RA patients, as these cells are uniquely resistant to Fas-mediated apoptosis [47]. This effect is due to an increased ac‐ tivity of SphK1 and an overproduction of S1P. In a murine experimental arthritis model, ad‐ ministration of SphK inhibitor, DMS, and of SphK1 siRNA significantly decreased the

S1P was also reported to induce chondrocyte proliferation through stimulation of COX-2 and PGE2 production and via activation of ERK [77,78], and was thus suggested to be able

Pathologic bone loss is a common feature of RA in which progressive destruction of bone is associated with joint inflammation. Focal bone erosion occurs at the pannus-bone interface and in the immediate subchondral bone early in RA, and is associated over time with signif‐ icant morbidity for patients [79]. Bone-resorbing osteoclasts have been identified as impor‐ tant effector cells in inflammation-induced bone loss in both experimental animal models and human RA. Osteoclasts are derived from hematopoietic precursor cells of the myeloid lineage [80,81]. In normal skeletal remodelling, the balance between bone resorption by os‐ teoclasts and bone formation by osteoblasts is critically regulated [82-84] and osteoclast dif‐ ferentiation is dependent on the presence of two key factors, RANKL and colonystimulating factor-1(CSF-1), provided by cells of the osteoblast lineage [81,85,86]. In experimental animal models of arthritis, osteoclasts have been observed at sites of focal bone

**and chondrocytes by S1P in the RA synovium**

10 Innovative Rheumatology

Both CIA and AIA are well-established models for studying RA. Administration of the S1P receptor agonist FYT720, which down-regulates S1P receptors, in rat CIA and AIA models inhibits rat hind paw oedema and joint destruction and decreases lymphocyte invasion into the joints [93,94]. In addition to receptor modulation, non-specific inhibition of SphK with DMS in a murine CIA model has been shown to significantly reduce adjacent cartilage and bone erosion, synovial hyperplasia, and inflammatory infiltration into the joint compart‐ ment [48,49]. Moreover, suppression of SphK1 via siRNA knockdown results in similar re‐ duction in joint pathology, serum levels of IL-6, TNF-α, IFN-γ and S1P, and the *in vitro* production of these proinflammatory mediators in response to collagen [48,49]. In another murine arthritis model, the transgenic human TNF-α model that develops spontaneous ero‐ sive arthritis, Sphk1-deficient mice exhibit significantly less synovial inflammation and joint pathology than the wild-type mice [95].

Interestingly, SphK isoforms may play different roles in RA. In a murine CIA model, downregulating SphK1 via specific small interfering RNA (siRNA) significantly reduced the inci‐ dence, disease severity, and articular inflammation. Treatment with SphK1 siRNA also down-regulated serum levels of S1P, IL-6, TNF-α, IFN-γ, and IgG2a anticollagen antibody [49]. On the other hand, mice receiving SphK2 siRNA developed a more aggressive disease, and higher serum levels of IL-6, TNF-α, and IFN-γ, when compared with control siRNA re‐ cipients. These results suggest distinct immunomodulatory roles for SphK1 and SphK2 in the development of inflammatory arthritis via the regulation of the release of proinflamma‐ tory cytokines and T cell responses.

S1P metabolism and SphK/S1P/S1P receptor axis-mediated signalling pathways in rheuma‐ toid arthritis synovium and the potential role of S1P in RA pathogenesis are illustrated in Figure 1 and Figure 2, respectively.

**Figure 2.** Potential role of S1P in the pathogenesis of RA.

flammation and destruction.

**4.1. Targeting S1P levels**

**4. Therapeutic POTENTIAL of S1P in rheumatoid arthritis**

The introduction of novel biological therapies in the mid-1990s markedly improved clinical outcomes in RA. Cytokine antagonists, such as biologic agents that inhibit TNF-α, IL-6, or IL-1β, decrease inflammation and joint destruction [96]. The impressive efficacy of these bio‐ logic agents, however, is only seen in about half of the patients. Similarly, B cell depletion and T cell co-stimulation blockers [96] are beneficial only in non- or partially-overlapping subsets of patients. There is undoubtedly a necessity to develop therapies that target other pathways. As S1P modulates RA pathogenesis in many aspects, manipulation of endoge‐ nous amounts of bioactive S1P and/or its receptor activation may be beneficial for joint in‐

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

13

Decreasing S1P level by inhibiting SphK1 activity may represent a therapeutic approach against RA. Blockage of SphK1 activity in an animal arthritis model indeed significantly suppressed articular inflammation and joint destruction, reduced disease severity, and

**Figure 1.** S1P metabolism and SphK/S1P/S1P receptor axis-mediated signalling pathways in RA synovium. S1P ho‐ meostasis is tightly regulated by the balance between its synthesis and degradation via three enzyme families: (1) Sphks (SphK1 and SphK2), which generate S1P through phosphorylation of its precursor, sphingosine (Sph), (2) SPPs (SPP1 and SPP2), which reversibly convert S1P back to Sph, and (3) SPL, which irreversibly degrades S1P to generate ethanolamine phosphate and hexadecenal. In the inflamed RA synovium, the specific binding of agonists, such as TNF-α, to their receptors (TNFR) induces the expression of SphKs, which in turn converts the membrane-bound Sph into S1P in synovial fibroblasts. The generated S1P then exits the cell through the ATP binding cassette (ABC) trans‐ porter and exerts its action through the G-protein coupled S1P receptors in an autocrine and/or paracrine fashion, activating specific S1P receptors presenting on the surface of the same cell or on nearby cells. Each S1P receptor cou‐ ples to a specific heterotrimeric G protein. When activated, the G protein dissociates into its α and βγ subunits and transduces signals toward the downstream pathways to regulate cell proliferation, growth, migration, apoptosis, etc. Extracellular S1P can stimulate the infiltration of immune cells, the proliferation and/or survival of synovial fibroblasts, B lymphoblastoid cells, and chondrocytes, as well as the osteoclastogenesis in the synovium. S1P also exerts its action as a second messenger via intracellular pathways, regulating chromatin states that impact gene transcription, cell growth and survival, and calcium mobilization independent of its G protein-coupled receptors. SM, sphingomyelin; Cer, ceramide; H, hexadecenal; E-P, ethanolamine phosphate; SMases, sphingomyelinases; CDases, ceramidases.

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets http://dx.doi.org/10.5772/53308 13

**Figure 2.** Potential role of S1P in the pathogenesis of RA.

#### **4. Therapeutic POTENTIAL of S1P in rheumatoid arthritis**

The introduction of novel biological therapies in the mid-1990s markedly improved clinical outcomes in RA. Cytokine antagonists, such as biologic agents that inhibit TNF-α, IL-6, or IL-1β, decrease inflammation and joint destruction [96]. The impressive efficacy of these bio‐ logic agents, however, is only seen in about half of the patients. Similarly, B cell depletion and T cell co-stimulation blockers [96] are beneficial only in non- or partially-overlapping subsets of patients. There is undoubtedly a necessity to develop therapies that target other pathways. As S1P modulates RA pathogenesis in many aspects, manipulation of endoge‐ nous amounts of bioactive S1P and/or its receptor activation may be beneficial for joint in‐ flammation and destruction.

#### **4.1. Targeting S1P levels**

**Figure 1.** S1P metabolism and SphK/S1P/S1P receptor axis-mediated signalling pathways in RA synovium. S1P ho‐ meostasis is tightly regulated by the balance between its synthesis and degradation via three enzyme families: (1) Sphks (SphK1 and SphK2), which generate S1P through phosphorylation of its precursor, sphingosine (Sph), (2) SPPs (SPP1 and SPP2), which reversibly convert S1P back to Sph, and (3) SPL, which irreversibly degrades S1P to generate ethanolamine phosphate and hexadecenal. In the inflamed RA synovium, the specific binding of agonists, such as TNF-α, to their receptors (TNFR) induces the expression of SphKs, which in turn converts the membrane-bound Sph into S1P in synovial fibroblasts. The generated S1P then exits the cell through the ATP binding cassette (ABC) trans‐ porter and exerts its action through the G-protein coupled S1P receptors in an autocrine and/or paracrine fashion, activating specific S1P receptors presenting on the surface of the same cell or on nearby cells. Each S1P receptor cou‐ ples to a specific heterotrimeric G protein. When activated, the G protein dissociates into its α and βγ subunits and transduces signals toward the downstream pathways to regulate cell proliferation, growth, migration, apoptosis, etc. Extracellular S1P can stimulate the infiltration of immune cells, the proliferation and/or survival of synovial fibroblasts, B lymphoblastoid cells, and chondrocytes, as well as the osteoclastogenesis in the synovium. S1P also exerts its action as a second messenger via intracellular pathways, regulating chromatin states that impact gene transcription, cell growth and survival, and calcium mobilization independent of its G protein-coupled receptors. SM, sphingomyelin; Cer, ceramide; H, hexadecenal; E-P, ethanolamine phosphate; SMases, sphingomyelinases; CDases, ceramidases.

12 Innovative Rheumatology

Decreasing S1P level by inhibiting SphK1 activity may represent a therapeutic approach against RA. Blockage of SphK1 activity in an animal arthritis model indeed significantly suppressed articular inflammation and joint destruction, reduced disease severity, and down-regulated proinflammatory cytokine production and inflammatory cell infiltration in‐ to the synovium [49]. In fact, inhibition of S1P synthesis by blocking SphK activity has pro‐ ven useful as an anti-inflammation strategy in cancer therapy [97-101].

modulation [116,117,120]. It differentially affects the sequestration of regulatory T-cells and increases their suppressive activity [121]. It is also reported to display anti-angiogenic activi‐ ty and to potently diminish angiogenesis and tumor vascularization *in vivo* in growth factor

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

15

FTY720 has been proven effective in the treatment of multiple sclerosis (MS). MS and RA are both autoimmune diseases with similar clinical inflammatory characterization, such as the infiltration of immune cells into the inflammatory sites, with RA affecting the joints, while MS affecting the brain and spinal cord. In MS, the most relevant effect of FTY720-P relates to its interaction with S1P1 receptor. After binding with the drug, S1P1 is internal‐ ized for several days. This receptor internalization, reduces the number of available S1P1 receptors and subsequently renders T lymphocytes unresponsive to S1P signals, which would otherwise mediate their migration from the thymus and lymph nodes to the pe‐ ripheral blood and from there to the brain. This way, FTY720 prevents lymphocytes from recirculating to peripheral sites of inflammation [124]. Treatment of human patients with relapsing-remitting MS with considerably low doses of FTY720 has proven to be benefi‐ cial [125,126].The results of a phase-II clinical trial, evaluating the efficacy and safety of FTY-720 for treating relapsing MS, showed that the annualized relapse rate of the FTY-720 group was significantly lower [126]. More recently, two large-scale, phase-III clinical trials conducted on relapsing-remitting MS patients demonstrated that FTY720 reduces relapse rates by more than 50%, as compared with the control groups [127,128]. FTY720, which can be taken orally [129], is therefore a highly promising immunomodulatory drug for MS. In fact, FTY720 has been approved by the US Food and Drug Administration for the

The therapeutic effect of FTY720 on RA was recently examined in animal models. FTY720 administration suppresses the progression of laminarin-induced arthritis in the SKG mice [130]. FTY720 treatment decreases IL-6 and TNF-α expression in synovial fibroblasts and in‐ flammatory cells, as well as bone destruction. The numbers of CD4+ and CD8+ T cells were significantly increased in the thymus and decreased in the spleen in FTY720-treated SKG mice. FTY720 enhanced IL-4 production by CD4+ T cells stimulated by allogeneic spleen cells and inhibited PGE2 production by a TNF-α-stimulated synovial fibroblast cell line. The anti-arthritic effect of FTY720 was also evaluated in AIA rats [131]. In that study, FTY720 treatment inhibited the incidence of arthritis, hind paw oedema and bone destruction. In ad‐ dition, it markedly decreased the number of peripheral blood lymphocytes. In a separate study, ovariectomized mice were injected with an arthrogenic anti-collagen II antibodies cocktail and then with lipopolysaccharide (LPS), so that they developed arthritis in their paws [132]. These mice thus exhibit both arthritis and osteoporosis and can be regarded as a model of elderly female RA patients. Results from this study showed that FTY720 was as potent as corticosteroid for suppressing arthritis. In addition, it induced recovery of the ovariectomy-induced bone density loss. These results clearly suggest that S1P-targeted ther‐ apy, such as S1P receptor agonists, would be beneficial for treating RA patients with both

implants and corneal models [122] and via the S1P1 receptor [123].

treatment of relapsing forms of MS.

immunological and bone resorptive disorders.

Depleting S1P level by utilizing S1P-blocking agents, such as specific antibodies, may also have therapeutic implications for RA. Indeed, anti-S1P antibodies have been developed and are currently tested in clinical studies for treatment of cancer, fibrosis, inflammation, macu‐ lar degeneration, diabetic retinopathy, glaucoma, and other diseases or symptoms (re‐ viewed in [102]). These antibodies bind to and inactivate S1P, reducing the extracellular pool of bioactive S1P and inhibiting its stimulating activity [103]. A preclinical study using block‐ ing S1P antibodies to prevent tumour progression, for example, was recently reported [104]. In that study, a specific anti-S1P monoclonal antibody reduced, and in some cases complete‐ ly eliminated, tumour formation and accompanying tumour angiogenesis. These results suggest that antibody-mediated inhibition of S1P signalling may be developed as a strategy for inhibiting pannus formation and angiogenesis in RA.

SPL, the major S1P-degrading enzyme, catalyzes the irreversible degradation of intracellu‐ lar S1P. Inhibition of SPL leads to the accumulation of S1P in tissues, including lymphoid tissues [105], and induces premature internalization of the exit-signal-sensing S1P1 recep‐ tor on lymphocytes, rendering them unresponsive to S1P and preventing their egress from thymus and lymph nodes [106]. One physiological outcome of this systemic redistribution of lymphocytes is potent immunosuppression, which offers new opportunities for devel‐ oping immunoregulatory agents to treat autoimmune and inflammatory diseases [107-111]. In fact, SPL-deficient mice showed resistance to various inflammatory and auto‐ immune challenges [112-114]. Early studies are undergoing on the application of SPL in‐ hibitors to RA treatment. The evaluation of a synthetic SPL inhibitor, LX2931, is currently in phase-II clinical trials in patients with active RA [112]. There are also studies on the SPL inhibitor, LX 3305, which inhibits lymphocyte migration, concerning its potential for RA clinical treatment [115].

#### **4.2. Targeting S1P receptors: S1P receptor agonist FTY720**

FTY720 (generic name fingolimod) is a synthetic sphingosine analog (2-amino-2-[2-(4-oc‐ tylphenyl)ethyl]propane-1,3-diol) that can be phosphorylated by SphKs. The designation FTY-P is used for the phosphorylated compound. FTY720 acts as an agonist with high af‐ finity for all S1P receptors except S1P2 [109], and very effectively down-regulates S1P re‐ ceptor expression [63,102]. It very actively induces the internalization, ubiquitylation and subsequent degradation of S1P receptors, consequently rendering cells unresponsive to S1P [63]. Compared to FTY720, S1P is much less effective at inducing receptor degrada‐ tion [116,117].

FTY720 has emerged as a clinically promising novel immunosuppressive drug that presum‐ ably acts by limiting effector lymphocyte egress from lymph nodes [118,119]. It rapidly in‐ duces lymphopenia through the sequestration of lymphocytes in lymph nodes and by blocking the emigration of mature thymocytes from the thymus through receptor downmodulation [116,117,120]. It differentially affects the sequestration of regulatory T-cells and increases their suppressive activity [121]. It is also reported to display anti-angiogenic activi‐ ty and to potently diminish angiogenesis and tumor vascularization *in vivo* in growth factor implants and corneal models [122] and via the S1P1 receptor [123].

down-regulated proinflammatory cytokine production and inflammatory cell infiltration in‐ to the synovium [49]. In fact, inhibition of S1P synthesis by blocking SphK activity has pro‐

Depleting S1P level by utilizing S1P-blocking agents, such as specific antibodies, may also have therapeutic implications for RA. Indeed, anti-S1P antibodies have been developed and are currently tested in clinical studies for treatment of cancer, fibrosis, inflammation, macu‐ lar degeneration, diabetic retinopathy, glaucoma, and other diseases or symptoms (re‐ viewed in [102]). These antibodies bind to and inactivate S1P, reducing the extracellular pool of bioactive S1P and inhibiting its stimulating activity [103]. A preclinical study using block‐ ing S1P antibodies to prevent tumour progression, for example, was recently reported [104]. In that study, a specific anti-S1P monoclonal antibody reduced, and in some cases complete‐ ly eliminated, tumour formation and accompanying tumour angiogenesis. These results suggest that antibody-mediated inhibition of S1P signalling may be developed as a strategy

SPL, the major S1P-degrading enzyme, catalyzes the irreversible degradation of intracellu‐ lar S1P. Inhibition of SPL leads to the accumulation of S1P in tissues, including lymphoid tissues [105], and induces premature internalization of the exit-signal-sensing S1P1 recep‐ tor on lymphocytes, rendering them unresponsive to S1P and preventing their egress from thymus and lymph nodes [106]. One physiological outcome of this systemic redistribution of lymphocytes is potent immunosuppression, which offers new opportunities for devel‐ oping immunoregulatory agents to treat autoimmune and inflammatory diseases [107-111]. In fact, SPL-deficient mice showed resistance to various inflammatory and auto‐ immune challenges [112-114]. Early studies are undergoing on the application of SPL in‐ hibitors to RA treatment. The evaluation of a synthetic SPL inhibitor, LX2931, is currently in phase-II clinical trials in patients with active RA [112]. There are also studies on the SPL inhibitor, LX 3305, which inhibits lymphocyte migration, concerning its potential for

FTY720 (generic name fingolimod) is a synthetic sphingosine analog (2-amino-2-[2-(4-oc‐ tylphenyl)ethyl]propane-1,3-diol) that can be phosphorylated by SphKs. The designation FTY-P is used for the phosphorylated compound. FTY720 acts as an agonist with high af‐ finity for all S1P receptors except S1P2 [109], and very effectively down-regulates S1P re‐ ceptor expression [63,102]. It very actively induces the internalization, ubiquitylation and subsequent degradation of S1P receptors, consequently rendering cells unresponsive to S1P [63]. Compared to FTY720, S1P is much less effective at inducing receptor degrada‐

FTY720 has emerged as a clinically promising novel immunosuppressive drug that presum‐ ably acts by limiting effector lymphocyte egress from lymph nodes [118,119]. It rapidly in‐ duces lymphopenia through the sequestration of lymphocytes in lymph nodes and by blocking the emigration of mature thymocytes from the thymus through receptor down-

ven useful as an anti-inflammation strategy in cancer therapy [97-101].

for inhibiting pannus formation and angiogenesis in RA.

**4.2. Targeting S1P receptors: S1P receptor agonist FTY720**

RA clinical treatment [115].

14 Innovative Rheumatology

tion [116,117].

FTY720 has been proven effective in the treatment of multiple sclerosis (MS). MS and RA are both autoimmune diseases with similar clinical inflammatory characterization, such as the infiltration of immune cells into the inflammatory sites, with RA affecting the joints, while MS affecting the brain and spinal cord. In MS, the most relevant effect of FTY720-P relates to its interaction with S1P1 receptor. After binding with the drug, S1P1 is internal‐ ized for several days. This receptor internalization, reduces the number of available S1P1 receptors and subsequently renders T lymphocytes unresponsive to S1P signals, which would otherwise mediate their migration from the thymus and lymph nodes to the pe‐ ripheral blood and from there to the brain. This way, FTY720 prevents lymphocytes from recirculating to peripheral sites of inflammation [124]. Treatment of human patients with relapsing-remitting MS with considerably low doses of FTY720 has proven to be benefi‐ cial [125,126].The results of a phase-II clinical trial, evaluating the efficacy and safety of FTY-720 for treating relapsing MS, showed that the annualized relapse rate of the FTY-720 group was significantly lower [126]. More recently, two large-scale, phase-III clinical trials conducted on relapsing-remitting MS patients demonstrated that FTY720 reduces relapse rates by more than 50%, as compared with the control groups [127,128]. FTY720, which can be taken orally [129], is therefore a highly promising immunomodulatory drug for MS. In fact, FTY720 has been approved by the US Food and Drug Administration for the treatment of relapsing forms of MS.

The therapeutic effect of FTY720 on RA was recently examined in animal models. FTY720 administration suppresses the progression of laminarin-induced arthritis in the SKG mice [130]. FTY720 treatment decreases IL-6 and TNF-α expression in synovial fibroblasts and in‐ flammatory cells, as well as bone destruction. The numbers of CD4+ and CD8+ T cells were significantly increased in the thymus and decreased in the spleen in FTY720-treated SKG mice. FTY720 enhanced IL-4 production by CD4+ T cells stimulated by allogeneic spleen cells and inhibited PGE2 production by a TNF-α-stimulated synovial fibroblast cell line. The anti-arthritic effect of FTY720 was also evaluated in AIA rats [131]. In that study, FTY720 treatment inhibited the incidence of arthritis, hind paw oedema and bone destruction. In ad‐ dition, it markedly decreased the number of peripheral blood lymphocytes. In a separate study, ovariectomized mice were injected with an arthrogenic anti-collagen II antibodies cocktail and then with lipopolysaccharide (LPS), so that they developed arthritis in their paws [132]. These mice thus exhibit both arthritis and osteoporosis and can be regarded as a model of elderly female RA patients. Results from this study showed that FTY720 was as potent as corticosteroid for suppressing arthritis. In addition, it induced recovery of the ovariectomy-induced bone density loss. These results clearly suggest that S1P-targeted ther‐ apy, such as S1P receptor agonists, would be beneficial for treating RA patients with both immunological and bone resorptive disorders.

## **5. Conclusion**

In summary, S1P, via SphK1/S1P/S1P-receptor signalling, appears to play an essential role in modulating RA pathogenesis since activated SphK1 and elevated level of S1P are detected in RA synovium. Moreover, S1P receptor expression is upregulated in inflamed synovium. S1P can stimulate proinflammatory cytokines/chemokines secretion, drive immune cell recruit‐ ment into inflammatory sites, and promote the proliferation and/or survival of synovial fi‐ broblasts, B lymphoblastoid cells, and chondrocytes. Although the mechanism of its effect in RA remains unclear, S1P represents an exploitable target for the development of a novel therapeutic approach for RA.

**Author details**

and Chenqi Zhao2

Medical University, Harbin, China

2010;69:1898-1906.

2009;59:382-389.

2009;50 Suppl:S91-96.

Pharmacol 2007;374:413-428.

\*Address all correspondence to: zhangzhiyi@medmail.com.cn

Faculty of Medicine, Laval University, Quebec, Canada

J Clin Invest 2008;118:3537-3545.

1 Department of Rheumatology and Immunology, The First Affiliated Hospital of Harbin

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

17

2 Rheumatology and Immunology Research Center, CHUQ-CHUL Research Center and

[1] Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis.

[2] McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis

[3] Kamada K, Arita N, Tsubaki T, Takubo N, Fujino T, Soga Y, Miyazaki T, Yamamoto H, Nose M. Expression of sphingosine kinase 2 in synovial fibroblasts of rheumatoid arthritis contributing to apoptosis by a sphingosine analogue, FTY720. Pathol Int

[4] Kitano M, Hla T, Sekiguchi M, Kawahito Y, Yoshimura R, Miyazawa K, Iwasaki T, Sano H, Saba JD, Tam YY. Sphingosine 1-phosphate/sphingosine 1-phosphate recep‐ tor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and in‐

[5] Zhao C, Fernandes MJ, Turgeon M, Tancrede S, Di Battista J, Poubelle PE, Bourgoin SG. Specific and overlapping sphingosine-1-phosphate receptor functions in human

[6] Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res

[7] Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell prolifera‐

[8] Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. Sphingosine-1-phos‐ phate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991;114:155-167.

[9] Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch

flammatory gene expression. Arthritis Rheum 2006;54:742-753.

synoviocytes: impact of TNF-alpha. J Lipid Res 2008;49:2323-2337.

tion induced by PDGF and FCS mitogens. Nature 1993;365:557-560.

Zhiyi Zhang1

**References**

## **6. Key Points**

	- **◦** Levels of S1P and its synthetic enzymes SphKs are elevated in RA synovium;
	- **◦** RA synovial fibroblasts are more responsive to S1P;
	- **◦** S1P stimulates the production of proinflammatory cytokines/chemokines by RA syno‐ vial fibroblasts;
	- **◦** S1P drives recruitment and retention of immune cells in RA synovium;
	- **◦** S1P promotes RA proliferation and/or survival of synovial fibroblasts, B cells, and chondrocytes;
	- **◦** S1P induces osteoclastogenesis in RA synovium; etc.
	- **◦** Decreasing S1P level by inhibiting SphK1 activity reduces RA disease severity in ani‐ mal models of arthritis;
	- **◦** Depleting S1P level by utilizing S1P-blocking agents inhibits the growth of tumours, which is relevant to pannus formation in RA;
	- **◦** The strategy of inhibiting SPL activity with the aim of rendering immune cells unre‐ sponsive to S1P and thus decreasing immune cells infiltration– is undergoing in phase-III clinical trials in patients with active RA;
	- **◦** Blocking S1P receptor activity by utilizing S1P receptor agonist FTY720 suppresses ar‐ thritis in animal models of RA; FTY720 has been approved by the US Food and Drug Administration for the treatment of relapsing forms of another chronic inflammatory disease multiple sclerosis.

## **Author details**

**5. Conclusion**

16 Innovative Rheumatology

**6. Key Points**

therapeutic approach for RA.

vial fibroblasts;

chondrocytes;

mal models of arthritis;

disease multiple sclerosis.

In summary, S1P, via SphK1/S1P/S1P-receptor signalling, appears to play an essential role in modulating RA pathogenesis since activated SphK1 and elevated level of S1P are detected in RA synovium. Moreover, S1P receptor expression is upregulated in inflamed synovium. S1P can stimulate proinflammatory cytokines/chemokines secretion, drive immune cell recruit‐ ment into inflammatory sites, and promote the proliferation and/or survival of synovial fi‐ broblasts, B lymphoblastoid cells, and chondrocytes. Although the mechanism of its effect in RA remains unclear, S1P represents an exploitable target for the development of a novel

**•** S1P plays an important role in rheumatoid arthritis pathogenesis. Proofs are:

**◦** S1P drives recruitment and retention of immune cells in RA synovium;

**◦** RA synovial fibroblasts are more responsive to S1P;

**◦** S1P induces osteoclastogenesis in RA synovium; etc.

which is relevant to pannus formation in RA;

III clinical trials in patients with active RA;

**◦** Levels of S1P and its synthetic enzymes SphKs are elevated in RA synovium;

**◦** S1P stimulates the production of proinflammatory cytokines/chemokines by RA syno‐

**◦** S1P promotes RA proliferation and/or survival of synovial fibroblasts, B cells, and

**◦** Decreasing S1P level by inhibiting SphK1 activity reduces RA disease severity in ani‐

**◦** Depleting S1P level by utilizing S1P-blocking agents inhibits the growth of tumours,

**◦** The strategy of inhibiting SPL activity – with the aim of rendering immune cells unre‐ sponsive to S1P and thus decreasing immune cells infiltration– is undergoing in phase-

**◦** Blocking S1P receptor activity by utilizing S1P receptor agonist FTY720 suppresses ar‐ thritis in animal models of RA; FTY720 has been approved by the US Food and Drug Administration for the treatment of relapsing forms of another chronic inflammatory

**•** S1P represents a potential therapeutic target for rheumatoid arthritis. Evidences are:

Zhiyi Zhang1 and Chenqi Zhao2

\*Address all correspondence to: zhangzhiyi@medmail.com.cn

1 Department of Rheumatology and Immunology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

2 Rheumatology and Immunology Research Center, CHUQ-CHUL Research Center and Faculty of Medicine, Laval University, Quebec, Canada

## **References**


[10] Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758:2016-2026.

[24] Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, Wattenberg BW, Va‐ das MA. Phosphorylation-dependent translocation of sphingosine kinase to the plas‐

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

19

[25] Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-

[26] Le Stunff H, Peterson C, Liu H, Milstien S, Spiegel S. Sphingosine-1-phosphate and

[27] Le Stunff H, Peterson C, Thornton R, Milstien S, Mandala SM, Spiegel S. Characteri‐ zation of murine sphingosine-1-phosphate phosphohydrolase. J Biol Chem

[28] Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from

[29] Sandhoff K, Kolter T. Biosynthesis and degradation of mammalian glycosphingoli‐

[30] Kobayashi N, Nishi T, Hirata T, Kihara A, Sano T, Igarashi Y, Yamaguchi A. Sphin‐ gosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated

[31] Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A

[32] Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, Tosaka M, Yoshimoto Y, Kuwabara A, Okajima F. Critical role of ABCA1 transporter in sphingosine 1-phos‐

[33] Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Bi‐

[34] Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin In‐

[35] Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-298.

[36] Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, Pham TH, Wong JS, Pappu R, Coughlin SR. Sphingosine-1-phosphate in the plasma compart‐ ment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest

[37] Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, Yang AH, Zhang G, Brown JH, Chun J. Marked perinatal lethality and cellular signaling deficits in

ma membrane drives its oncogenic signalling. J Exp Med 2005;201:49-54.

phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-195.

lipid phosphohydrolases. Biochim Biophys Acta 2002;1582:8-17.

modular to integrative signaling. Biochemistry 2001;40:4893-4903.

phate release from astrocytes. J Neurochem 2007;103:2610-2619.

pids. Philos Trans R Soc Lond B Biol Sci 2003;358:847-861.

manner. J Lipid Res 2006;47:614-621.

2002;277:8920-8927.

2006;103:16394-16399.

ochem 2004;92:913-922.

vest 2000;106:951-961.

2009;119:1871-1879.


[24] Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, Wattenberg BW, Va‐ das MA. Phosphorylation-dependent translocation of sphingosine kinase to the plas‐ ma membrane drives its oncogenic signalling. J Exp Med 2005;201:49-54.

[10] Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta

[11] Sekiguchi M, Iwasaki T, Kitano M, Kuno H, Hashimoto N, Kawahito Y, Azuma M, Hla T, Sano H. Role of sphingosine 1-phosphate in the pathogenesis of Sjogren's syn‐

[12] Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, Watsky MA. Elevated serum levels of arachidonoyl-lysophosphatidic acid and

[13] Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biolo‐

[14] Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phos‐

[15] Ito K, Anada Y, Tani M, Ikeda M, Sano T, Kihara A, Igarashi Y. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun

[16] Murata N, Sato K, Kon J, Tomura H, Okajima F. Quantitative measurement of sphin‐ gosine 1-phosphate by radioreceptor-binding assay. Anal Biochem 2000;282:115-120.

[17] Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F. In‐ teraction of sphingosine 1-phosphate with plasma components, including lipopro‐ teins, regulates the lipid receptor-mediated actions. Biochem J 2000;352 Pt 3:809-815.

[18] Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mecha‐

[19] Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem

[20] Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-

[21] Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat

[22] Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regu‐

[23] Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extrac‐ ellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-ace‐

sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009;6:168-176.

2006;1758:2016-2026.

18 Innovative Rheumatology

2007;357:212-217.

1998;273:23722-23728.

Rev Mol Cell Biol 2003;4:397-407.

drome. J Immunol 2008;180:1921-1928.

gy. Annu Rev Biochem 2004;73:321-354.

phate in blood. FASEB J 2007;21:1202-1209.

nisms of regulation. Biochem Cell Biol 2004;82:27-44.

phosphate. Trends Endocrinol Metab 2007;18:300-307.

tate (PMA). J Biol Chem 2002;277:35257-35262.

lation and role in disease. J Biochem Mol Biol 2006;39:113-131.


mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem 2002;277:25152-25159.

Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses.

http://dx.doi.org/10.5772/53308

21

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

[51] Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. An‐

[52] Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid

[53] Nochi H, Tomura H, Tobo M, Tanaka N, Sato K, Shinozaki T, Kobayashi T, Takagishi K, Ohta H, Okajima F, Tamoto K. Stimulatory role of lysophosphatidic acid in cyclo‐ oxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fi‐

[54] Huang MC, Watson SR, Liao JJ, Goetzl EJ. Th17 augmentation in OTII TCR plus T cell-selective type 1 sphingosine 1-phosphate receptor double transgenic mice. J Im‐

[55] Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res

[56] Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of colla‐ gen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-6177.

[57] Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol

[58] Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovi‐

[59] Ghosh M, Stewart A, Tucker DE, Bonventre JV, Murphy RC, Leslie CC. Role of cyto‐ solic phospholipase A(2) in prostaglandin E(2) production by lung fibroblasts. Am J

[60] Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a po‐

[61] Mino T, Sugiyama E, Taki H, Kuroda A, Yamashita N, Maruyama M, Kobayashi M. Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prosta‐ glandin E2-dependent production of interleukin-11 in rheumatoid synovial fibro‐

[62] Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phos‐ phate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem

tential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-87.

al cells of rheumatoid arthritis patients. Mol Cells 2005;19:180-184.

Cell Signal 2007;19:748-760.

munol 2007;178:6806-6813.

Ther 2005;7:R784-795.

1998;160:3513-3521.

2004;279:15396-15401.

Respir Cell Mol Biol 2004;30:91-100.

blasts. Arthritis Rheum 1998;41:2004-2013.

nu Rev Immunol 1996;14:397-440.

arthritis. Immunol Rev 2010;233:233-255.

broblast-like synovial cells. J Immunol 2008;181:5111-5119.


Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 2007;19:748-760.

[51] Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. An‐ nu Rev Immunol 1996;14:397-440.

mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5

[38] Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion

[39] Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello E, Vivier E. Natural killer cell trafficking in vivo requires a

[41] Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate recep‐

[42] Olivera A, Rosenfeldt HM, Bektas M, Wang F, Ishii I, Chun J, Milstien S, Spiegel S. Sphingosine kinase type 1 induces G12/13-mediated stress fiber formation, yet pro‐ motes growth and survival independent of G protein-coupled receptors. J Biol Chem

[43] Taha TA, Argraves KM, Obeid LM. Sphingosine-1-phosphate receptors: receptor spe‐ cificity versus functional redundancy. Biochim Biophys Acta 2004;1682:48-55. [44] Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Mar‐ morstein R, Kordula T, Milstien S, Spiegel S. Regulation of histone acetylation in the

[45] van Koppen CJ, Meyer zu Heringdorf D, Alemany R, Jakobs KH. Sphingosine kin‐ ase-mediated calcium signaling by muscarinic acetylcholine receptors. Life Sci

[46] Xia P, Wang L, Gamble JR, Vadas MA. Activation of sphingosine kinase by tumor ne‐ crosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem

[47] Pi X, Tan SY, Hayes M, Xiao L, Shayman JA, Ling S, Holoshitz J. Sphingosine kinase 1-mediated inhibition of Fas death signaling in rheumatoid arthritis B lymphoblas‐

[48] Lai WQ, Irwan AW, Goh HH, Howe HS, Yu DT, Valle-Onate R, McInnes IB, Melen‐ dez AJ, Leung BP. Anti-inflammatory effects of sphingosine kinase modulation in in‐

[49] Lai WQ, Irwan AW, Goh HH, Melendez AJ, McInnes IB, Leung BP. Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J Immunol

[50] Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, Cai R, Zemann B, Urtz N, Stingl G, Zlabinger G, Woisetschlager M, Baumruker T, Billich A.

nucleus by sphingosine-1-phosphate. Science 2009;325:1254-1257.

dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8:1337-1344. [40] Choi JW, Lee CW, Chun J. Biological roles of lysophospholipid receptors revealed by

genetic null mice: an update. Biochim Biophys Acta 2008;1781:531-539.

and S1P(3)/LP(B3)/EDG-3. J Biol Chem 2002;277:25152-25159.

without signaling migration. FASEB J 2005;19:1731-1733.

tor signaling. Annu Rev Biochem 2009;78:743-768.

2003;278:46452-46460.

20 Innovative Rheumatology

2001;68:2535-2540.

1999;274:34499-34505.

2009;183:2097-2103.

toid cells. Arthritis Rheum 2006;54:754-764.

flammatory arthritis. J Immunol 2008;181:8010-8017.


[63] Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid or‐ gans is dependent on S1P receptor 1. Nature 2004;427:355-360.

[76] Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in pa‐

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

23

[77] Kim MK, Lee HY, Kwak JY, Park JI, Yun J, Bae YS. Sphingosine-1-phosphate stimu‐ lates rat primary chondrocyte proliferation. Biochem Biophys Res Commun

[78] Masuko K, Murata M, Nakamura H, Yudoh K, Nishioka K, Kato T. Sphingosine-1 phosphate attenuates proteoglycan aggrecan expression via production of prosta‐ glandin E2 from human articular chondrocytes. BMC Musculoskelet Disord

[79] Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford)

[80] Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology

[81] Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T. Macrophage colony-stimulating factor is indispensable for both proliferation

[82] Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass.

[83] Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function.

[84] Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteo‐

[85] Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveirados-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lympho‐

[86] Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and acti‐

[87] Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakasima A, Iijima T. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with ac‐ companying disordered high bone turnover. Histol Histopathol 1998;13:751-759. [88] Suzuki Y, Nishikaku F, Nakatuka M, Koga Y. Osteoclast-like cells in murine collagen

cyte development and lymph-node organogenesis. Nature 1999;397:315-323.

clastogenesis and bone disease. Trends Mol Med 2006;12:17-25.

and differentiation of osteoclast progenitors. J Clin Invest 1993;91:257-263.

tients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.

2006;345:67-73.

2007;8:29.

2000;39 Suppl 1:24-29.

1988;123:2600-2602.

Nature 2003;423:349-355.

Nat Rev Genet 2003;4:638-649.

vation. Cell 1998;93:165-176.

induced arthritis. J Rheumatol 1998;25:1154-1160.


[76] Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in pa‐ tients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.

[63] Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid or‐

[64] Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clo‐ zel M. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther

[65] Chen X, Oppenheim JJ, Howard OM. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chi‐

[66] Zhao C, Sardella A, Chun J, Poubelle PE, Fernandes MJ, Bourgoin SG. TNF-alpha promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through

[67] Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis.

[68] Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Firestein, GS; Budd, RC; Harris, T; McInnes, IB; Ruddy, S; Sergent, JS, editors Kelly's Textbook of

[69] Pap TG, S. Fibroblasts and fibroblast-like synoviocytes. In: Firestein, GS; Budd, RC; Harris, T; McInnes, IB; Ruddy, S; Sergent, JS, editors Kelly's Textbook of Rheumatol‐

[70] Knedla A, Neumann E, Muller-Ladner U. Developments in the synovial biology field

[71] Dechanet J, Merville P, Durand I, Banchereau J, Miossec P. The ability of synovio‐ cytes to support terminal differentiation of activated B cells may explain plasma cell

[72] Hayashida K, Shimaoka Y, Ochi T, Lipsky PE. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-

[73] Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlym‐ phoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc

[74] Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-4718.

[75] Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical signifi‐

Rheumatology 8. Philadelphia, PA: Saunders Elsevier; 2009:1035-1086.

accumulation in rheumatoid synovium. J Clin Invest 1995;95:456-463.

CD106-dependent mechanism. J Immunol 2000;164:1110-1116.

gans is dependent on S1P receptor 1. Nature 2004;427:355-360.

nese medicinal components. Cell Mol Immunol 2004;1:336-342.

CXCR2 ligand chemokines. J Lipid Res 2011;52:1307-1318.

ogy 8 Philadelphia, PA: Saunders Elsevier; 2009:201-214.

2011;337:547-556.

22 Innovative Rheumatology

Front Biosci 2004;9:2323-2334.

2006. Arthritis Res Ther 2007;9:209.

Natl Acad Sci U S A 1996;93:221-225.

cance. Arthritis Res 2002;4 Suppl 2:S1-5.


[89] Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004;16:419-427.

[102] Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

25

[103] Sabbadini RA. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer

[104] Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphin‐ gosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion,

[105] Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte se‐ questration through S1P lyase inhibition and disruption of S1P gradients. Science

[106] Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to

[107] Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid sig‐

[108] Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008;75:1893-1900.

[109] Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor

[110] Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medul‐ lary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingo‐ sine 1-phosphate receptor agonist. Proc Natl Acad Sci U S A 2003;100:10907-10912.

[111] Zhang Z, Schluesener HJ. FTY720: a most promising immunosuppressant modulat‐

[112] Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopina‐ than S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ. In‐ hibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disor‐

[113] Bandhuvula P, Fyrst H, Saba JD. A rapid fluorescence assay for sphingosine-1-phos‐

[114] Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, Anderson SJ, Sun W, Swaffield J, Oravecz T. Incomplete inhibition of sphingosine 1-phosphate lyase mod‐

ing immune cell functions. Mini Rev Med Chem 2007;7:845-850.

phate lyase enzyme activity. J Lipid Res 2007;48:2769-2778.

and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225-238.

lymphoid organ transit. J Exp Med 2005;201:291-301.

naling. Trends Mol Med 2006;12:65-75.

agonists. Science 2002;296:346-349.

ders. J Med Chem 2009;52:3941-3953.

1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-553.

2006;95:1131-1135.

2005;309:1735-1739.


[102] Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-553.

[89] Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and

[90] Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J

[91] Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in

[92] Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates

[93] Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol

[94] Wang F, Tan W, Guo D, He S. Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. Eur J Pharmacol

[95] Baker DA, Barth J, Chang R, Obeid LM, Gilkeson GS. Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine

[96] Bingham CO, 3rd. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt

[97] Billich A, Bornancin F, Mechtcheriakova D, Natt F, Huesken D, Baumruker T. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory media‐

[98] Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells

[99] French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of

[100] Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, Vadas MA. Phenox‐ odiol, an experimental anticancer drug, shows potent antiangiogenic properties in

[101] Leroux ME, Auzenne E, Evans R, Hail N, Jr., Spohn W, Ghosh SC, Farquhar D, McDonnell T, Klostergaard J. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma

sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596-603.

addition to its antitumour effects. Int J Cancer 2006;118:2412-2420.

TNF-alpha-induced arthritis. J Immunol 2010;185:2570-2579.

by targeting sphingosine kinase-1. Leukemia 2006;20:95-102.

treatment strategies. Curr Opin Rheumatol 2004;16:419-427.

2006;25:5840-5851.

24 Innovative Rheumatology

2000;22:323-331.

2007;573:230-240.

Dis 2008;66:210-215.

tors. Cell Signal 2005;17:1203-1217.

cells. Prostate 2007;67:1699-1717.

vivo. J Exp Med 2010; 207:2793-2798.

bone homeostasis. Nature 2009;458:524-528.


ulates immune system function yet prevents early lethality and non-lymphoid le‐ sions. PLoS One 2009;4:e4112.

[126] Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclero‐

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

http://dx.doi.org/10.5772/53308

27

[127] Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Cap‐ ra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclero‐

[128] Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Ag‐ oropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral

[129] Martin R. Multiple sclerosis: closing in on an oral treatment. Nature 2010;464:360-362.

[130] Tsunemi S, Iwasaki T, Kitano S, Imado T, Miyazawa K, Sano H. Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol

[131] Matsuura M, Imayoshi T, Chiba K, Okumoto T. Effect of FTY720, a novel immuno‐ suppressant, on adjuvant-induced arthritis in rats. Inflamm Res 2000;49:404-410.

[132] Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthri‐ tis with monoclonal antibodies to collagen. J Immunol 1992;148:2103-2108.

fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.

sis. N Engl J Med 2006;355:1124-1140.

sis. N Engl J Med 2010;362:402-415.

2010;136:197-204.


[126] Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclero‐ sis. N Engl J Med 2006;355:1124-1140.

ulates immune system function yet prevents early lethality and non-lymphoid le‐

[115] Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr

[116] Gonzalez-Cabrera PJ, Hla T, Rosen H. Mapping pathways downstream of sphingo‐ sine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J

[117] Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY, Hla T. Im‐ munosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem

[118] Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin

[119] Okamoto H, Takuwa N, Yokomizo T, Sugimoto N, Sakurada S, Shigematsu H, Taku‐ wa Y. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or

[120] Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling over‐ rides retention mediated by G alpha i-coupled receptors to promote T cell egress. Im‐

[121] Sawicka E, Dubois G, Jarai G, Edwards M, Thomas M, Nicholls A, Albert R, Newson C, Brinkmann V, Walker C. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhan‐

[122] LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vas‐

[123] Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, Bruns CJ, Jauch KW, Heeschen C, Graeb C. The immunosuppressant FTY720 inhibits tumor angiogenesis

[124] Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, Proia RL, Cyster JG. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic mar‐

via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007;101:259-270.

[125] Kahan BD. Frontiers in immunosuppression. Transplant Proc 2008;40:11-15.

ces their functional activity. J Immunol 2005;175:7973-7980.

sions. PLoS One 2009;4:e4112.

26 Innovative Rheumatology

Opin Rheumatol 2012;24:335-341.

Biol Chem 2007;282:7254-7264.

2007;282:9082-9089.

Invest 2012;122:1416-1426.

munity 2008;28:122-133.

EDG3. Mol Cell Biol 2000;20:9247-9261.

cularization. Cancer Res 2006;66:221-231.

ginal zone. Nat Immunol 2004;5:713-720.


**Chapter 2**

**New Therapeutic Targets for the Control of**

Maria das Graças Muller de Oliveira Henriques

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53738

**1. Introduction**

processes [8,9,10,11].

**Inflammatory Arthritis: A Pivotal Role for Endothelins**

Rheumatoid arthritis (RA) is a complex, debilitating, chronic, systemic autoimmune disease characterised by immunological, inflammatory and mesenchymal tissue reactions in the synovium that are accompanied by polyarticular synovitis and ultimately lead to the progres‐ sive destruction of articular and periarticular structures [1,2]. A critical factor that contributes to joint damage is the excessive production of inflammatory mediators by resident and/or infiltrating inflammatory cells. Among the main mediators involved in the join damage process are free radicals, extracellular matrix–degrading enzymes, pro-inflammatory cyto‐ kines, including interleukin(IL)-6, IL-1 and tumour necrosis factor (TNF)-α, as well as chemo‐

Endothelins (ETs) are a family of naturally occurring peptides [6] with well-established growth-promoting, vasoactive, and nociceptive properties that affect the function of a number of tissues and systems [7]. ETs have pathophysiological roles in pulmonary hy‐ pertension, arterial hypertension, atherosclerosis, cerebral vasospasm and inflammatory

Recently, new evidence has demonstrated that endogenous endothelins (ETs) also play a role in articular inflammation by regulating inflammatory pain, edema formation, leukocyte influx and the production of inflammatory mediators. The present chapter attempts to provide an overview of the evidence accumulated to date, which suggests that ETs play a pivotal role in ar‐ ticular inflammation, and the blockade of these endogenous peptides can represent a promis‐ ing therapeutic tool for the treatment of RA and other articular inflammatory diseases. To address this issue in a comprehensive manner, however, it is important to briefly provide some fundamental aspects of endothelin biosynthesis and release as well as information about the re‐

> © 2013 Henriques; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,

© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,

distribution, and reproduction in any medium, provided the original work is properly cited.

and reproduction in any medium, provided the original work is properly cited.

kines, such as CXCL1, and lipid mediators, such as leukotriene (LT)B4 [3,4,5].

ceptors that they interact with and the modes of action of these peptides.
